Qiagen (QGEN) Reports In-Line Q4 EPS, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
- Hertz cuts guidance, announces notes and stock offerings, shares sink
QIAGEN Reports Results for Fourth Quarter and Full-Year 2018
February 4, 2019 4:04 PM ESTQIAGEN delivers on full-year 2018 outlook FY 2018: Achieved 6% CER net sales growth to $1.5 billion vs. ~6-7% CER outlook and adj. diluted EPS of $1.34 ($1.35 CER vs. ~$1.33-1.34 CER outlook) FY 2018: Adj. operating income margin rises to 27% of sales from 26% in 2017 and operating cash flow rises 25% to $359.5 million Q4 2018: Net sales of $403.2 million +2%, +5% CER vs. ~6-7% CER outlook; diluted EPS of $0.26; adj. EPS $0.40 ($0.41 CER vs. ~$0.39-0.40 CER outlook) Delivering 2018 growth from dynamic and disruptive Sample to Insight portfolio QuantiFERON-TB delivers 21% CER full-year growth... More
